Loading
A phase 1/2 trial of Datopotamab deruxtecan in non-small-cell lung cancer and triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) is a phase 1/2 interventional study registered as NCT05460273 by AstraZeneca, with 119 participants enrolled, started 2022-07-11 and due to reach its primary completion in 2023-11-07. Interventions recorded: Datopotamab Deruxtecan (Dato-DXd). Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
119 enrolled.
95% CI 23.4 to 45.4; Figures from the ClinicalTrials.gov results section (first posted 2025-06-13), not from a publication · 95% CI 29.3 to 61.5
Source95% CI 10.7 to NA; Figures from the ClinicalTrials.gov results section (first posted 2025-06-13), not from a publication · 95% CI 13.8 to 20.4
SourceThe full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Daiichi Sankyo, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Daiichi Sankyo, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/